2026-02-25 15:13:27

$RXRX

Recursion Pharmaceuticals GAAP EPS of -$0.21 beats by $0.08, revenue of $35.54M beats by $10.98M
Feb 25, 2026,
Q4 GAAP EPS of -$0.21 beats by $0.08.
Revenue of $35.54M (+681.1% Y/Y) beats by $10.98M.
Cash, cash equivalents and restricted cash were $753.9 million as of December 31, 2025 compared to $603.0 million as of December 31, 2024.
Based on current operating plans and with no additional financing, the Company’s expected cash runway extends into early 2028.
Net cash used in operating activities was $46.1 million for the fourth quarter of 2025, compared to net cash used in operating activities of $115.4 million for the fourth quarter of 2024.
Cash operating expense, excluding partnership inflows and transaction costs, for the year ended December 31, 2025 was $399.2 million.
Neither with it nor without it... it has a toxic communication style. You say it’s over, it comes back; you say it started, it drops

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.